Emil Kakkis has been a big advocate for an adaptive trial design (in particular for rare diseases where populations are small and efficacy could be small/take long to show significance). Perhaps its time to explore these/other changes to speed development?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.